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Abstract
Background/Aim. Graves’ ophthalmopthy is one of the
most common causes of exophthalmos as well as the most
common manifestation of Graves’ disease. The treatment of
Graves’ ophthalmopathy includes ophthalmological and en-
docrinological therapy. The aim of this study was to clinically
evaluate the patients with Graves’ ophthalmopathy treated
with corticosteroids. Methods. Evaluation of 21 patients was
performed in the Ophthalmology Clinic and Endocrinology
Clinic, Clinical Centre Kragujevac, in the period from 2009 to
2010. They were treated with pulse doses of intravenous corti-
costeroids. They were referred to ophthalmologist by endocri-
nologist in euthyroid condition in the active phase of Graves’
ophthalmopathy (ultrasonography of orbit findings and posi-
tive findings of antithyroid stimulating hormone receptor anti-
body – anti-TSH R Ab). The clinical activity score (CAS) and
NO SPECS classification for evaluation of disease severity
were used. Ophthalmological examination includes: best cor-
rected visual acuity, slit-lamp exam, Hertels’ test, direct oph-
thalmoscopy and ultrasonography of the orbit. Results. Ac-
cording to our results 76.19% of the patients were female;
mean age of the patients was 35.2 ± 5.6 years. According to
CAS classification after 6 months of the treatment recovery
was shown in 23.81% of the patients, partial amelioration in
47.62% and no clinical amelioration in 28.57% of the patients.
We achieved better results with male, young patients with high
clinical activity score. Good results were observed after the
first dose of corticosteroids, much better CAS after the third
dose, which maintained until 6 months after the first treat-
ment. Conclusion. Our results signify that intravenous pulse
dose of corticosteroids treatment of the patients with Graves’
ophthalmopthy is safe, comfortable, clinically justified and ac-
cessible for the clinicians and patients. Positive results are
achieved after the first dose with increasing trend up to the
third dose, which was maintained for the next three months.
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hormones; convalescence.
Apstrakt
Uvod/Cilj. Grejvsova oftalmopatija najčešći je uzrok egzof-
talmusa i najčešća ekstratireoidna manifestacija bolesti. Za leče-
nje aktivne faze bolesti koriste se kortikosteroidi. Cilj rada bio je
evaluacija lečenja bolesnika sa Grejvsovom oftalmopatijom tre-
tiranih kortikosteroidnom terapijom. Metode. Ispitivan je 21
bolesnik u aktivnoj fazi bolesti, koji su u eutireoidnom statusu
tretirani pulsnim dozama intravenskih (iv) kortikosteroida u
Klinici za oftalmologiju i Klinici za endokrinologiju Kliničkog
Centra Kragujevac, od 01. 01. 2009. do 31. 12. 2010. Aktivnost
Grejvsove oftalmopatije potvrđena je ultrazvučnim pregledom
orbite (oftalmolog) i određivanjem koncentracije antitela na re-
ceptore tireostimulišućeg hormona (TSH) ab (endokrinolog).
Procena aktivnosti bolesti određivana je skorom kliničke aktiv-
nosti (Clinical Activity Score – CAS), a stepen težine bolesti NO
SPECS klasifikacijom koja određuje kliničke aspekte ispitivanja
i praćenja oftalmopatije. Klinički pregled oftalmologa obuhva-
tao je: određivanje vidne oštrine, biomikroskopski pregled, di-
rektnu oftalmoskopiju, egzoftalmometriju i ultrazvučni pregled
orbite. Rezultati. Među ispitanicima bilo je 76,19% pripadnika
ženskog pola. Prosečna starost bolesnika bila je 35,2 ± 5,6 go-
dina. Analiza podataka prema CAS klasifikaciji, posle šest me-
seci pokazala je: potpuni oporavak kod 23,81% bolesnika, a
kod 47,62% parcijalni oporavak, dok kod 28,57% bolesnika
nije bilo kliničkog poboljšanja. Bolji terapijski rezultati postig-
nuti su kod pripadnika muškog pola, mlađih, sa većom klinič-
kom aktivnošću bolesti. Prvi pozitivni rezulati postižu se nakon
prve doze kortikosteroida, bolji posle treće doze, a održavaju se
na nivou, šest meseci posle prve doze lečenja. Zaključak. Naši
rezultati ukazuju na visoku efikasnost lečenja bolesnika sa
Grejvsovom oftalmopatijom primenom iv pulsnih doza korti-
kosteroida. Ovakav tretman je bezbedan i komforan i za lekara
i za bolesnika. Pozitivni rezutlati vidljivi su već posle prve doze
kortikosteroida uz tendenciju poboljšanja posle treće doze, što
se održava tokom sledeća tri meseca.
Ključne reči:
gušavost, egzoftalmička; tireotropin; antitela; bolest,
indeks težine; klasifikacioni indeksi; kortikosteroidni
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Introduction
Graves’ ophthalmopathy (GO) is one of the most com-
mon causes of exophthalmos and the most common cause of
morbidity and discomfort in patients with Graves’ disease
 1.
The first document about Graves’ disease was found in 1786
by Perry, but a complete clinical manifestation was described
in 1835 by Basedow
 2. Ophthalmopathy is a manifestation of
autoimmune process with the expressed extraocular myositis,
glicosaminoglican production, orbital congestion and mono-
nuclear orbital infiltration. The main causes of GO are ge-
netic (positive findings of HLA-A8, HLA-DR3) and the in-
fluence of surroundings (stress, smoking cigarettes, infec-
tion)
 3. The disease is more frequent in female patients, with
the ratio 3–10 : 1, and the mean age is 41 years, 2.5 years
after the beginning of the disease. The more difficult form of
the disease is described in male patients, at the age of 50
 3.
Clinical manifestation of the disease is typical and self-
limited with active (progressive exacerbation) and inactive
phase (regression and stagnation). Werner et al. 
4 classified
clinical signs of the disease in NO SPECS system, and clas-
sification was modified in 1981 to RELIEF classification.
The clinical activity score (CAS) is based on 4 of the 5 clas-
sical signs of inflammation and has 10 well-known items.
For each item, one point can be given. The sum of these
points is CAS (range 0–10)
 5, 6. The diagnosis can be proved
by endocrinologist and ophthalmologist. Computerized to-
mography (CT) and nuclear magnetic resonance (NMR) are
reserved for unclear clinical manifestations of the disease
 7.
Intravenous (iv) pulse doses of corticosteroids are used for
the treatment of the active phase GO. Their action is medi-
ated by inhibition of polymorphonuclear migration
 8. Side ef-
fects of corticosteroid treatment are rarely reported. Some of
them like weight gain, hypertension, diabetes mellitus in-
duction, pyloric ulcer, osteoporosis and the most difficult of
them – fatal autoimmune hepatitis, can be notified
 9. Indica-
tions for this treatment are: euthyroid condition of patients,
positive findings of anti thyroid stimulating hormone recep-
tor anti-body (anti-TSH R Ab), extraocular muscle hypertro-
phy without fibrosing.
The aim of our study was to evaluate the patients with
GO treated with corticosteroids iv pulse doses of.
Methods
We examined 21 patients with the active phase of GO
in euthyroid condition, treated with iv pulse doses of cortico-
steroid therapy in the Ophthalmology Clinic and Endocrinol-
ogy Clinic, Clinical Centre Kragujevac, from January 1,
2009 until December 31, 2010. The active phase of GO was
confirmed by orbital ultrasonography, positive finding of
anti-TSH R Ab and clinical activity was classified by CAS
and disease degree was classified by NO SPECS classifica-
tion (Tables 1, 2). Ophthalmological examination included:
best corrected visual acuity (Snellen table), slit-lamp exami-
nation, direct ophthalmoscopy, Hertels’ exophtalmometry
and orbital ultrasonography. The patients were referred to
ophthalmologist by endocrinologist with a detailed endocri-
nological status. All the patients were classified according to
the duration of the disease into 3 groups: 1 – duration less
than 1 year, 2 – duration from 1 to 2 years and 3 – duration
for more than 2 years. The patients with active phase GO
were treated with iv pulse doses of corticosteroids with Ethi-
cal Committee approval. We used iv pulse doses of corticos-
teroids (methylpredisolone 1 g/24 h for 3 days) followed by
corticosteroides per os, 40 mg/24 h seven days, with a de-
creasing dose for 10 mg every week to the next pulse dose.
Our patients were treated with 3 cycles of pulse dose every
fourth week. Before the treatment the patients were exam-
ined for the clinical parameters: arterial pressure, glycemia
and the serum liver enzymes level, as well as basic blood ex-
amination. During the treatment, there were no complica-
tions related to the corticosteroid therapy. The patients were
ophthalmologically examined after 4 weeks, 3 and 6 months.
We evaluated CAS and NO SPECS signs values in our pa-
tients analyzed by SPSS, version 13.
Table 1
NO SPECS (underlined first letter) and RELIEF (bolded
first letter) categorization of Graves’ophthalmopathy
Classification Signs and symptoms
0 No signs and symptoms
1 Only signs are upper eyelid retraction
2 Softe tissue signs and symptoms
Resistance to retropulsation
Edema of conjunctiva or caruncula
Lacrimal gland enlargement
Injection over the horizontal rectus
muscle insertion
Edema of eyelid
Fullness of the eyelid
3 Proptosis
4 Extraocular muscle involvement
5 Corneal involvement
6 Sight loss
Table 2
Clinical Activity Score
Symptoms/Signs Description
Pain 1 –  Painfull, oppresive feeling on or
behind the globe, during the last
2 –  Pain or attempted up, side or down
gaze, during the last 4 weeks
Redness 3 –  Redness of the eyelid(s)
Swelling 4 –  Diffuse redness of the conjunctiva,
covering at least one quadrant
5 –  Swelling of the eyelid
6 –  Chemosis
7 –  Swollen caruncle
8 –  Increase of proptosis of  ≥ 2 mm
during 1–3 minutes
Impaired
function
9 –  Decrease of eye movements in any
direction ≥ 5°, 1–3 months
10 – Decrease of visual acuity of ≥ 1 line
on Snellen chart (using pinhole),
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Results
According to our results, 16/21 (76.19%) of the patients
were female, with a clinically significant manifestation of the
disease (χ² = 5.762, p = 0.016). The mean age of the patients
was 35.2 ± 5.6 years. Clinical activity measured by CAS was
≥  4 in 80.95%. According to NO SPECS classification,
71.43% of the patients had class 2 of the disease with a sig-
nificant differences (χ² = 14, p = 0.001). There were 14.28%
of the patients in the third class and 19.04% patients in the
first class. There were no patients in the lower class of the
NO SPECS classification. After 4 weeks of the treatment
there were no statistically significant differences about the
distribution of patients by NO SPECS classification (in the
class 0 – 19.04%, class 1 – 42.86%, class 2 – 33.33%,
class > 3 – 4.76%;  χ² = 7.0, p = 0.072). After the third iv
pulse dose of corticosteroids, a great number of the patients
was in the class 1 – 38.10%, then in the class 2 – 33.33%
with increasing number of patients in the class 0 – 28.57%,
but with no statistically significant differences (χ² = 0.286, p
= 867). After 6 months, a great number of the patients was in
the class 1 – 47.62%, in the class 2 – 23.81%, but without
patients in the hardest class 3, with no statistically significant
differences (χ² = 2.0, p = 0.368) (Table 3). According to our
results classified in CAS, best results were reached after 6
months – complete remission in 23.81%, partial remission in
47.62%, without remission in 28.57% of the patients, without
statistically significant differences (χ² = 2.0, p = 0.368). The
results after 4 weeks were: complete remission in 19.04%,
partial remission in 42.86%, without remission in 38.10% of
the patients, with no statistically significant differences
(χ² = 2.0, p = 0.368). After 3 months we achieved complete
remission in 23.81%, incomplete remission in 42.86%, no
remission in 28.57%, without statistically significant differ-
ences (χ² = 2.0, p = 0.368). It means that many clinical signs
decreased in their manifestation after corticosteroid treat-
ment. After 4 weeks of the beginning of the treatment we
summarized the number of patients with a complete and in-
complete remission, when we reached no statistically signifi-
cant differences (χ² = 5.762,  p  =  0.275), but after 3 and 6
months we got statistically significant differences in the
number of patients with complete and incomplete remission
(χ² = 3.857, p = 0.005). There were no statistically significant
differences in these analysis, but we were able to notify great
changes in the variables during the examination, with a sig-
nificantly better clinical status of the patients after the first
dose of the iv pulse dose of corticosteroids, with increasing
trend after the second and the third dose maintained until 6
months after the beginning of the treatment. A complete and
incomplete remission was achieved in male patients. A com-
plete remission was achieved in 19.04% of females, incom-
plete remission in 28.57%, without remission in 28.57%. Ac-
cording to these results we can notify that at the very begin-
ning of the corticosteroid treatment a great number of pa-
tients had incomplete remission with trend for increasing ef-
fectiveness of the therapy. A complete remission was
achieved in 14.28% of all patients younger than 40 years,
followed by 33.33% with incomplete remission. All the pa-
tients without remission were older than 40 years. There was
a significant difference related to the age of the patients and
the results of the therapy. The group of the younger patients
(<  40 years) had better results (χ² = 12.095,  p = 0.02).  A
complete recovery was noted in the group with CAS > 4, in-
complete in 33.33 % of the patients with CAS > 4 and in
14.28% of patients with CAS ≤ 4, but all the patients with-
out recovery had CAS ≤ 4 (Table 4). There were no signifi-
cant differences between the duration of the disease and the
results of the therapy. In the group of patients with the dura-
tion of the disease less than 2 years, complete recovery was
achieved in 9.52%, incomplete in 19.05% and without re-
covery in 2 patients. In the group of patients with the disease
Table 3
Distribution of patients according to NO SPECS
classification, after 4 weeks, 3 and 6 months
NO SPECS classification* Duration of drug therapy 012 ≥ 3
Before treatment 4 15 2
After 4 weeks 4 9 7 1
After 3 months 6 8 7
After 6 months 5 10 6
*see Table 1
Table 4
Effects of the therapy according to the CAS classification, sex, age and disease degree
Parameters Recovery (number of patients)
complete incomplete partial no recovery
Duration of drug treatment
after 4 weeks
after 3 months
after 6 months
4
5
5
9
9
10
8
7
6
Sex
male
female
4
4
1
6
0
6
Age (years)
> 40
< 40
2
3
3
7
5
1
CAS*
≤ 4
< 4 5
3
7
6
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duration of one to two years, complete recovery was
achieved in 9.52%, incomplete in 14.28% and without re-
covery in 9.52% of the patients. In the group of patients with
the disease duration more than 2 years, complete recovery
was noted in 4.76%, incomplete in 14.28% and without re-
covery in 2 patients.
Before the treatment all the patients were examined
(arterial pressure, blood examination, liver enzimes). All the
patients were treated with gastroprotective therapy. Cushing-
oid syndrome was detected in 18 (85.71%) patients, but after
the treatment it was regulated. During the treatment transito-
rial hypertension was notified in 2 patients, but arterial pre-
assure was regulated at the end of the treatment. We notified
weight gain in all the patients, but after 3 months of the
treatment it was also regulated. There were no elevation of
the serum liver enzimes values.
Discussion
Rundle at all.
 10 notified that Graves’ ophthalmopathy has
two phases, interrupted with a “plate” phase: initial phase with
high activity after 6–24 months from the beginning of the dis-
ease and the phase of incomplete regression. Early symptoms
are a consequence of autoimmune process and inflammation.
The later ones are a consequence of the fibrosing process.
Some earlier studies indicated that there is no correlation be-
tween the disease duration and the treatment effects as well as
in our study
 6. The active phase of GO can be treated with cor-
ticosteroids and the late one can be treated with radiation and
surgical therapies
 11. Peroral steroids were used for the treat-
ment of the active phase of GO, but better results were
achieved with intravenous steroids
 11. There are some data
about using rituximab (anti-CD20), etancerot (anti-TNF), oc-
treotide, somatostatin, plasmapheresis, etc.
 3, 12. Corticosteroid
therapy in our opinion has many advantages, such as lower
costs and lower number of side effects and contraindications
 11.
Very important predictive factor for the efficiency of cortico-
steroid therapy are CAS values. Good results were noted in the
group of patients with CAS > 4 and bad results in the group
with CAS ≤ 4. In this fashion our results are similar to other
records
 13. The majority of the patients were younger female
patients (< 40 years). The best results were noted in younger
male patients (< 40 years). The efficacy of the therapy in the
female group was 66.66%. Incomplete recovery was noted in
76.19% of the patients with lower CAS values, according to
other investigations
 13. The younger patients had better effects
of the corticosteroid therapy. Euthyroid status of the patient
was of great importance during the whole therapy in our in-
vestigation.
Conclusion
Our results signify that intravenous pulse dose of corti-
costeroids treatment of the patients with Graves’ ophthal-
mopthy is safe, comfortable, clinically justified and accessi-
ble for the clinicians and patients. Positive results are
achieved after the first dose with increasing trend up to the
third dose, which was maintained for the next three months.
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